Coronary heart disease (CHD) remains the leading cause of death in the United States, yet the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of 39%. In practical terms, this means that many who appear healthy go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors including cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable.
To address this blind spot, Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics—fields that examine how genes are expressed and regulated at the molecular level. These tests aim to provide molecular precision to risk assessment, potentially identifying patients who would otherwise be missed by traditional screening methods. The company's approach seeks to move beyond the limitations of conventional risk calculators, which have an average sensitivity of only 39%, meaning they fail to detect CHD in more than 60% of cases.
The implications of this announcement are significant. If widely adopted, epigenetic and genetic testing could transform preventive cardiology by catching disease earlier in patients who do not fit the classic risk profile. This could lead to earlier interventions, reduced rates of heart attacks, and lower healthcare costs associated with late-stage cardiac care. The technology represents a shift from population-based risk scoring to individualized molecular assessment.
For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. Forward-looking statements in this article are subject to risks and uncertainties as described in the company's SEC filings.
